Rheumatology 2002; 41: 981-987
© 2002 British Society for Rheumatology
Original papers |
Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999
The Centre for Rheumatology, Middlesex Hospital, Arthur Stanley House, 40–50 Tottenham Street, London, W1P 9PG and
1 The Department of Histopathology, University College Hospital, University Street, London W1N 8AA, UK
Objective. To review the development, histological type and outcome of a cohort of patients with lupus nephritis who were managed and followed up by the specialist Bloomsbury Rheumatology Unit between 1977 and 1999.
Patients and methods. Seventy-eight of the 280 (28%) patients with systemic lupus erythematosus (SLE) developed nephritis. Occurrence of end stage renal disease (ESRD) according to World Health Organization (WHO) class was analysed, and patients were subdivided according to whether treatment included at least six pulses of intravenous (i.v.) cyclophosphamide (CYC) once a month.
Results. For patients with WHO class III nephritis, three out of five treated with i.v. CYC developed ESRD compared with none out of 10 not treated with i.v. CYC (P < 0.02). There was no significant difference between these subgroups in terms of a variety of parameters with good prognostic value, except anti-dsDNA titre at time of biopsy (which was greater in the former). For patients with WHO class IV nephritis, three out of 16 treated with i.v. CYC developed ESRD, compared with five out of 20 not treated with i.v. CYC (no significant difference).
Conclusion. These data suggest that there may be a subgroup of patients with lupus nephritis (WHO class III) whose long-term outcome is not adversely affected by the omission of i.v. CYC.
KEY WORDS: Lupus nephritis, Cyclophosphamide, WHO class.
Correspondence to: D. A. Isenberg, The Centre for Rheumatology, Middlesex Hospital, Arthur Stanley House, 40–50 Tottenham Street, London WIP 9PG, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. A. Isenberg, J. J. Manson, M. R. Ehrenstein, and A. Rahman Fifty years of anti-ds DNA antibodies: are we approaching journey's end? Rheumatology, July 1, 2007; 46(7): 1052 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Bastian, G. S. Alarcon, J. M. Roseman, G. McGwin Jr, L. M. Vila, B. J. Fessler, J. D. Reveille, and for the LUMINA study group Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria Rheumatology, April 1, 2007; 46(4): 683 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Adler, S. Chambers, C. Edwards, G. Neild, and D. Isenberg An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period Rheumatology, September 1, 2006; 45(9): 1144 - 1147. [Abstract] [Full Text] [PDF]
|
|